Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

474 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The contemporary concept of significant versus insignificant prostate cancer.
Ploussard G, Epstein JI, Montironi R, Carroll PR, Wirth M, Grimm MO, Bjartell AS, Montorsi F, Freedland SJ, Erbersdobler A, van der Kwast TH. Ploussard G, et al. Among authors: van der kwast th. Eur Urol. 2011 Aug;60(2):291-303. doi: 10.1016/j.eururo.2011.05.006. Epub 2011 May 17. Eur Urol. 2011. PMID: 21601982 Review.
Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors.
Paris PL, Andaya A, Fridlyand J, Jain AN, Weinberg V, Kowbel D, Brebner JH, Simko J, Watson JE, Volik S, Albertson DG, Pinkel D, Alers JC, van der Kwast TH, Vissers KJ, Schroder FH, Wildhagen MF, Febbo PG, Chinnaiyan AM, Pienta KJ, Carroll PR, Rubin MA, Collins C, van Dekken H. Paris PL, et al. Among authors: van dekken h, van der kwast th. Hum Mol Genet. 2004 Jul 1;13(13):1303-13. doi: 10.1093/hmg/ddh155. Epub 2004 May 11. Hum Mol Genet. 2004. PMID: 15138198
Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC)--Section Rotterdam. A comparison of two rounds of screening.
Postma R, Schröder FH, van Leenders GJ, Hoedemaeker RF, Vis AN, Roobol MJ, van der Kwast TH. Postma R, et al. Among authors: van leenders gj, van der kwast th. Eur Urol. 2007 Jul;52(1):89-97. doi: 10.1016/j.eururo.2007.01.030. Epub 2007 Jan 16. Eur Urol. 2007. PMID: 17257742 Clinical Trial.
Strong immunohistochemical expression of fibroblast growth factor receptor 3, superficial staining pattern of cytokeratin 20, and low proliferative activity define those papillary urothelial neoplasms of low malignant potential that do not recur.
Barbisan F, Santinelli A, Mazzucchelli R, Lopez-Beltran A, Cheng L, Scarpelli M, van der Kwast T, Montironi R. Barbisan F, et al. Cancer. 2008 Feb 1;112(3):636-44. doi: 10.1002/cncr.23212. Cancer. 2008. PMID: 18072261 Free article.
Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study.
Burger M, van der Aa MN, van Oers JM, Brinkmann A, van der Kwast TH, Steyerberg EC, Stoehr R, Kirkels WJ, Denzinger S, Wild PJ, Wieland WF, Hofstaedter F, Hartmann A, Zwarthoff EC. Burger M, et al. Among authors: van der aa mn, van der kwast th, van oers jm. Eur Urol. 2008 Oct;54(4):835-43. doi: 10.1016/j.eururo.2007.12.026. Epub 2007 Dec 26. Eur Urol. 2008. PMID: 18166262
Interobserver variability between expert urologic pathologists for extraprostatic extension and surgical margin status in radical prostatectomy specimens.
Evans AJ, Henry PC, Van der Kwast TH, Tkachuk DC, Watson K, Lockwood GA, Fleshner NE, Cheung C, Belanger EC, Amin MB, Boccon-Gibod L, Bostwick DG, Egevad L, Epstein JI, Grignon DJ, Jones EC, Montironi R, Moussa M, Sweet JM, Trpkov K, Wheeler TM, Srigley JR. Evans AJ, et al. Among authors: van der kwast th. Am J Surg Pathol. 2008 Oct;32(10):1503-12. doi: 10.1097/PAS.0b013e31817fb3a0. Am J Surg Pathol. 2008. PMID: 18708939
474 results